CEO Swami Raote said, “We are pleased to welcome Lior to our Global Executive Team and look forward to his active engagement as we keep scaling our geographic presence, expand our capacity, new products, and partnerships portfolio.”
-
Latest News PolyNovo announces appointment of general counsel and company secretary May 7, 2024
-
Latest News Scholarships open for supporting women into STEM careers May 7, 2024The Australian Academy of Technological Sciences and Engineering has opened applications for the third round of the Elevate: Boosting women in STEM scholarship program.
-
Latest News Illumina partners with the Garvan on major new genome project May 2, 2024Global genomics company Illumina is partnering with the Garvan Institute of Medical Research’s TenK10K project on a joint $27 million investment to map 50 million human cells from 10,000 people.
-
AusBiotech Industry applauds funding commitment for National One Stop Shop for clinical trials May 2, 2024The biotechnology, medical technology, and pharmaceutical industries have welcomed the announcement of $18.8 million in funding for the National One Stop Shop for clinical trials.
-
Latest News Anatara Lifesciences announces the completion of successful placement May 2, 2024Anatara Lifesciences (ASX:ANR) has announced that it has received firm commitments for a placement to raise a total of $1 million before costs.
-
Latest News Chimeric Therapeutics announces resignation of CEO and managing director May 2, 2024Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that its CEO and managing director, Jennifer Chow, has given notice of her resignation.
-
Latest News Immutep reports positive initial clinical data from EFTISARC-NEO study May 2, 2024Immutep (ASX:IMM) has announced initial encouraging data from EFTISARC-NEO, a Phase 2 investigator-initiated trial of eftilagimod alpha in combination with radiotherapy, a standard-of-care treatment, plus MSD's KEYTRUDA (pembrolizumab) for patients with soft tissue sarcoma.
-
Latest News Alterity Therapeutics presents new data demonstrating potential of ATH434 April 30, 2024Alterity Therapeutics (ASX:ATH) has announced that new data on its lead drug candidate, ATH434, was presented at the World Orphan Drug Congress USA 2024 in Boston.
-
AusBiotech AusMedtechInvest keynote and panel speakers announced April 30, 2024The programme for Australia’s inaugural boutique medtech investment roundtable, AusMedtechInvest 2024, is packed and features speakers from leading investment firms ARCHIMED, Artesian, Brandon Capital, Main Sequence, OneVentures, and Tenmile, as well as investment pitch presentations from medtech executives.
-
Latest News FivepHusion announces ethics approval of Phase 1b trial of deflexifol as first-line treatment April 30, 2024FivepHusion has announced that the Human Regulatory Ethics Committee has approved the next clinical trial of Deflexifol.
-
Latest News Mesoblast announces the appointment of new board chair April 30, 2024Mesoblast (ASX:MSB) has announced that Joseph Swedish has chosen to step down as chair and will remain on the board until completion of his term at the company's annual general meeting later this year.
-
Latest News Opyl expands coverage TrialKey of clinical trial prediction and design optimisation April 30, 2024Opyl (ASX:OPL) has confirmed the recent expansion of its TrialKey.ai AI-driven platform. It says this marks a significant milestone in clinical trial prediction and design optimisation.
-
AusBiotech AusBiotech announces incoming CEO April 23, 2024Australia’s industry body for biotechnology, AusBiotech, has announced ex-Sanofi leader Rebekah Cassidy as its incoming Chief Executive Officer.
-
Latest News Osteopore launches first first-in-human clinical trials begin in Singapore April 23, 2024Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has announced the commencement of first-in-human clinical trials for knee preservation in Singapore.
-
Latest News Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate April 23, 2024Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."
-
Latest News BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics April 23, 2024Bristol Myers Squibb has joined Brandon Capital, a leading Australian life sciences private equity firm, in supporting Pathios Therapeutics' Series B financing.
-
Latest News Mark Butler announces NHMRC funding for six telehealth research projects April 23, 2024The Albanese Government has announced that the National Health and Medical Research Council will invest $5 million in six research projects focused on telehealth.
New Stories
-
Island announces reallocation of US grant funding to support den
May 8, 2024 - - AusBiotech -
Echo IQ submits application seeking FDA approval of AI-supported heart diagnostic
May 7, 2024 - - Latest News -
TGA seeks nominations for statutory advisory committees
May 7, 2024 - - AusBiotech -
PolyNovo announces appointment of general counsel and company secretary
May 7, 2024 - - Latest News -
Scholarships open for supporting women into STEM careers
May 7, 2024 - - Latest News -
CUREator deploys $7.21 Million to propel local life sciences potential
May 7, 2024 - - Latest News -
Industry applauds funding commitment for National One Stop Shop for clinical trials
May 2, 2024 - - AusBiotech